A woman on DMPA for 8 years asks about the recent MHRA safety communication regarding medroxyprogesterone acetate and meningioma risk. What should she be told? A There is no association between DMPA and meningioma B High-dose medroxyprogesterone acetate (including injectable formulations) may be associated with an increased risk of meningioma with prolonged use; DMPA is now contraindicated in women with a current or past meningioma C Only oral medroxyprogesterone carries this risk D The risk only applies to use beyond 20 years E She must stop DMPA immediately regardless of history
Check my answer
Educational content. Not a substitute for clinical judgement or local policy.